MannKind Corporation to Participate in 2021 RBC Capital Markets Global Healthcare Conference
May 11 2021 - 9:00AM
MannKind Corporation (Nasdaq: MNKD), a company
focused on the development and commercialization of inhaled
therapeutic products for patients with endocrine and orphan lung
diseases, announced today that its Chief Executive Officer, Michael
Castagna, PharmD, will participate in a Fireside Chat at the 2021
RBC Capital Markets Global Healthcare Conference on Tuesday, May
18, 2021 at 4:15 pm (ET). Interested parties can access a link to
the webcast from the Events & Presentations section of the
Company's website at http://www.mannkindcorp.com. The webcast
replay will remain available for 14 days following the live
presentation.
About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on
the development and commercialization of inhaled therapeutic
products for patients with endocrine and orphan lung diseases.
MannKind is currently commercializing Afrezza® (insulin human)
Inhalation Powder, the Company’s first FDA-approved product and the
only inhaled ultra rapid-acting mealtime insulin in the United
States, where it is available by prescription from pharmacies
nationwide. Afrezza is also available by prescription
in Brazil where it is commercialized by the Company’s
partner Biomm SA. MannKind is headquartered in
Westlake Village, California, with a manufacturing and R&D
facility in Danbury, Connecticut. The Company also employs field
sales and medical representatives across the U.S. Please visit
www.mannkindcorp.com to learn more.
Contact:818-661-5000ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Jul 2024 to Aug 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Aug 2023 to Aug 2024